Published in World J Gastroenterol on March 28, 2014
Elevated risk of venous thromboembolic events in patients with inflammatory myopathies. Vasc Health Risk Manag (2016) 0.79
Care of inflammatory bowel disease patients in remission. Gastroenterol Rep (Oxf) (2016) 0.75
Cerebral venous thrombosis in a patient with Crohn's disease. Intest Res (2016) 0.75
Hospital-Acquired Conditions Are Associated with Worse Outcomes in Crohn's Disease-Related Hospitalizations. Dig Dis Sci (2017) 0.75
Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet (2010) 5.63
Guidelines for the management of inflammatory bowel disease in adults. Gut (2011) 5.42
Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (2010) 5.20
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med (2007) 3.33
Vascular complications of inflammatory bowel disease. Mayo Clin Proc (1986) 3.00
Bidirectional relation between inflammation and coagulation. Circulation (2004) 3.00
The interactions between inflammation and coagulation. Br J Haematol (2005) 2.92
Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut (2004) 2.55
Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol (2006) 2.50
The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost (2001) 2.31
Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology (2000) 2.22
Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol (2008) 2.09
Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med (2007) 1.95
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut (2011) 1.70
Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol (2004) 1.69
Inflammatory bowel disease-associated thromboembolism: a systematic review of outcomes with anticoagulation versus catheter-directed thrombolysis. Inflamm Bowel Dis (2011) 1.50
Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis (2012) 1.49
Cerebral and retinal vascular complications of inflammatory bowel disease. Ann Neurol (1979) 1.42
Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol (2011) 1.27
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology (2010) 1.23
Cerebrovascular complications of inflammatory bowel disease. Am J Gastroenterol (1991) 1.21
Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis (2011) 1.18
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol (2006) 1.17
Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol (2003) 1.15
Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol (2008) 1.07
Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum (2012) 1.06
Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2013) 1.01
Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther (2007) 1.00
Physicians' perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci (2012) 0.98
A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol (2013) 0.96
Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther (2000) 0.96
Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig Dis Sci (2005) 0.95
The influence of glutathione and other thiols on human platelet aggregation. Thromb Res (1986) 0.95
Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease. Haemostasis (1998) 0.94
Deep venous thrombosis after surgery for inflammatory bowel disease: is standard dose low molecular weight heparin prophylaxis enough? World J Surg (2010) 0.94
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. Dig Dis (2008) 0.90
Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. J Crohns Colitis (2013) 0.89
Mesenteric venous thrombosis in inflammatory bowel disease. J Clin Gastroenterol (2005) 0.88
Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. J Crohns Colitis (2013) 0.86
The incidence of postoperative venous thrombosis among patients with ulcerative colitis. Ir J Med Sci (2005) 0.85
Portomesenteric vein thrombosis in patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.84
Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment Pharmacol Ther (2000) 0.82
Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis. Am J Gastroenterol (2013) 0.78
Recurrent deep vein thrombosis despite warfarin therapy in a patient with Crohn's disease. Postgrad Med (2010) 0.76